CS
MNTA

Candriam SCA’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Candriam SCA’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-219,575
Closed -$11.5M – 875
2020
Q3 		$11.5M Sell
219,575
-187,445
-46% -$7.76M 0.11% 209
2020
Q2 		$13.5M Buy
+407,020
New +$13M 0.14% 168
2018
Q4 		– Sell
-396,300
Closed -$10.4M – 863
2018
Q3 		$10.4M Sell
396,300
-40,200
-9% -$1.09M 0.14% 185
2018
Q2 		$8.93M Buy
436,500
+78,500
+22% +$1.68M 0.14% 186
2018
Q1 		$6.5M Buy
358,000
+11,000
+3% +$183K 0.11% 233
2017
Q4 		$4.84M Sell
347,000
-75,000
-18% -$1.01M 0.08% 272
2017
Q3 		$7.81M Buy
422,000
+55,000
+15% +$919K 0.14% 184
2017
Q2 		$6.2M Buy
367,000
+157,000
+75% +$2.39M 0.12% 209
2017
Q1 		$2.8M Buy
210,000
+140,000
+200% +$2.19M 0.05% 374
2016
Q4 		$1.05M Hold
70,000
– – 0.02% 507
2016
Q3 		$818K Buy
+70,000
New +$823K 0.02% 529

Candriam SCA's MNTA Position: Q4 2020 in Review

Candriam SCA sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 219,575 shares — an estimated $11.5M sold.

Candriam SCA first reported a position in MNTA in Q3 2016 and held it in 11 quarters. The position peaked at $13.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Candriam SCA reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Candriam SCA sold 219,575 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $11.5M.
  • Candriam SCA first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 11 quarters.
  • Candriam SCA's Momenta Pharmaceuticals, Inc. position peaked at $13.5M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.